myrawtruth.com
What myrawtruth.com actually is
myrawtruth.com is not really a standalone content website in the usual sense. When opened, it redirects straight into AbbVie’s official RINVOQ page for atopic dermatitis, specifically a page comparing RINVOQ with DUPIXENT and walking visitors through trial results, treatment differences, and safety information. That matters because it tells you the domain is functioning as a campaign entry point, not as an independent health publisher or community resource.
This kind of setup is common in pharmaceutical marketing. A short, memorable domain gets used in TV spots, social ads, or influencer-style placements, then funnels people into a branded destination that carries the full prescribing and safety disclosures. In this case, that is exactly what seems to be happening. Mentions of myrawtruth.com in ad tracking and broadcast transcript pages line up with eczema-focused ads telling viewers to visit the site and talk to a dermatologist about symptoms and treatment options.
What the site is trying to do
It is built as a conversion path, not an information library
Once the redirect lands, the page is structured around a very specific job: move a person with moderate to severe eczema closer to asking a doctor about RINVOQ. You can see that in the page layout. It highlights head-to-head trial results, puts RINVOQ and DUPIXENT side by side, offers a “Doctor Discussion Guide,” and repeats calls to talk with a healthcare provider.
That does not automatically make the information false. But it does frame the site’s purpose clearly. The content is there to persuade within a regulated environment. It is not there to neutrally map the full treatment landscape for eczema.
The branding choice is deliberate
The phrase “my raw truth” sounds personal, almost diary-like. That is not accidental. It softens the commercial feel and makes the entry point sound more like a patient story or a self-advocacy tool than a branded drug page. Then, after the click, the visitor is inside a tightly controlled pharmaceutical experience. From a marketing standpoint, that is smart. From a user standpoint, it means you should understand the jump you are making. The domain name feels personal; the destination is corporate and product-specific.
What you learn from the redirect destination
The message is centered on comparative performance
The landing page emphasizes a head-to-head trial between RINVOQ and DUPIXENT, including claims around itch relief and skin clearance at 4 and 16 weeks. The site says more than twice as many people achieved both little to no itch and 90% clearer skin with RINVOQ versus DUPIXENT at 16 weeks, while also noting that conclusions comparing two active therapies cannot be made from a single clinical trial alone. That disclaimer is important because it shows the usual tension in pharma pages: strong promotional framing, followed by carefully worded limitations.
This is one of the more interesting parts of the site. It is not hiding the comparison inside dense medical copy. The comparison is the headline. So the website is less about “What is eczema?” and more about “Here is why this treatment deserves your attention right now.”
It also leans hard on patient action tools
The “Doctor Discussion Guide” is one of the clearest signals of intent. That feature is not mainly educational in the abstract. It is built to prepare someone for a treatment conversation in a clinic. Again, that is very common in branded health sites. The goal is to move the patient from passive browsing into a more specific treatment discussion with a prescriber.
Where the website is credible, and where it is limited
Credible in the narrow, official sense
Because the redirect goes to AbbVie’s official RINVOQ domain, the material is tied to the manufacturer’s approved product communications. The broader RINVOQ eczema site states that the medicine is indicated for adults and children 12 years and older with moderate to severe atopic dermatitis whose disease did not respond adequately to prior treatment and is not well controlled with other pills or injections, including biologics, or when those treatments are not recommended. AbbVie also has a 2022 announcement covering the FDA approval for this eczema indication.
So the site is not some random lead-gen page pretending to be medical advice. It is attached to a real drug, real labeling, and real manufacturer disclosures.
Limited because it is still product marketing
That same official status is also the limitation. The website is not a broad eczema resource in the way the National Eczema Association is. NEA provides condition-level information, education, and support that is not centered on selling one medication. By contrast, myrawtruth.com exists to route users into one branded treatment story.
That distinction matters a lot. If someone lands there looking for balanced guidance on all treatment options, they are not getting the full picture. They are getting a polished slice of the picture that supports one product’s positioning.
The safety piece is not optional here
RINVOQ has serious warnings, and the site does disclose them
One thing the destination page does correctly is make the safety burden impossible to ignore. It includes boxed warning language and lists serious risks such as serious infections, cancer and immune system problems, major cardiovascular events, blood clots, allergic reactions, tears in the stomach or intestines, and lab abnormalities. The FDA labeling for upadacitinib also carries these major warnings.
That is important because a lot of consumer health pages try to make safety feel like a footnote. This page does not bury it entirely. The warning content is extensive. Still, the overall architecture of the experience is designed so benefits get attention first and risk gets absorbed afterward, which is pretty standard in direct-to-consumer pharma advertising.
The comparison with DUPIXENT is persuasive, but not neutral
The page explicitly notes that RINVOQ and DUPIXENT have different FDA-approved uses and different safety profiles. It also notes the study was not designed to compare safety. Those caveats matter. A casual visitor could easily walk away with “RINVOQ beat DUPIXENT,” while missing the more careful point that efficacy and safety need to be weighed in a much broader clinical context.
That is probably the single most important reading tip for this website: do not treat a head-to-head promotional page as the same thing as a full treatment decision framework.
Why the website exists at all
It solves an ad problem
TV and social ads need memorable URLs. A long branded address like a deep rinvoq.com eczema comparison page is not practical in a 15-second spot. myrawtruth.com is short, easy to remember, and emotionally framed around the patient experience. Then the redirect does the rest. Independent ad references make that pattern pretty visible.
It also reflects how pharma now markets to patients
This site is a good example of modern pharmaceutical direct-to-consumer strategy. Instead of pushing only disease awareness or only hard-brand recall, it blends both. The entry point sounds like patient truth-telling. The destination is a specific branded treatment funnel. That combination is effective because it lowers resistance at the first click.
Key takeaways
- myrawtruth.com is a vanity or campaign domain that redirects to AbbVie’s official RINVOQ eczema pages, rather than operating as an independent website.
- Its real purpose is marketing: get people with moderate to severe eczema to consider RINVOQ and discuss it with a dermatologist.
- The destination page uses trial comparisons against DUPIXENT as a central persuasive device, while also attaching the usual legal and clinical caveats.
- The information is official in the sense that it comes from the manufacturer and aligns with the drug’s approved use, but it is not neutral or comprehensive.
- Anyone using the site should read it as branded health communication, then cross-check with broader condition resources and a clinician, especially because RINVOQ carries significant safety warnings.
FAQ
Is myrawtruth.com a scam?
There is no strong sign from the available evidence that it is a scam site. The domain redirects into AbbVie’s official RINVOQ website, which is a legitimate pharmaceutical property.
Is myrawtruth.com an independent eczema resource?
No. It may look personal from the domain name, but in practice it is a branded gateway into a RINVOQ marketing and information flow.
What condition is the website about?
It is focused on eczema, specifically atopic dermatitis, and more specifically on moderate to severe disease where systemic treatment is being considered.
Why does the site compare RINVOQ and DUPIXENT?
Because the comparison is being used to frame RINVOQ as a strong treatment option for eligible patients. The page is designed to influence treatment discussions, not just explain eczema in general.
Should someone rely on this website alone for treatment decisions?
No. It is useful for seeing how AbbVie presents RINVOQ, but it should be balanced with independent condition resources and a doctor’s guidance because the drug has significant warnings and because the site is not neutral.
Post a Comment